Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials
Obesity · 2025
DOI: 10.1002/oby.24348 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Obesity, 2025. Verfasst von Evgenia Gourgari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology, Department of Pediatrics, Georgetown University, Washington, DC, USA. Hauptthemen laut MEDLINE: Obesity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Objective
People with early‐onset obesity (diagnosed at age < 25 years) may present with more cardiometabolic abnormalities and obesity‐related complications. This post hoc analysis assessed baseline characteristics and body weight (BW) changes with tirzepatide in people with early‐ versus later‐onset obesity.
Methods
Participants ( N = 3782) from SURMOUNT‐1, SURMOUNT‐3, and SURMOUNT‐4 randomized to tirzepatide or placebo were included. Baseline characteristics and changes in BW and cardiometabolic risk factors at 72/88 weeks were assessed.
Results
In SURMOUNT‐1, participants with early‐ versus later‐onset obesity had longer mean obesity duration (20 ± 12 vs. 11 ± 8 years), higher BMI (40 ± 7 vs. 37 ± 6 kg/m 2 ) and waist circumference (WC, 118 ± 16 vs. 112 ± 14 cm), and lower HbA1c (5.48% ± 0.4% vs. 5.60% ± 0.4%), triglycerides (median 120 vs. 130 mg/dL), and systolic blood pressure (SBP; 121 ± 13 vs. 125 ± 13 mmHg) at baseline (all p ≤ 0.004). At 72 weeks, improvements with tirzepatide in BW (−23% vs. −22%), WC (−22 vs. −19 cm), HbA1c (−0.51% vs. −0.52%), triglycerides (−32% vs. −31%), and SBP (−8 vs. −8 mmHg) were similar between subgroups. Similar improvements were observed in SURMOUNT‐3 and SURMOUNT‐4.
Conclusions
In this post hoc analysis, participants with early‐ versus later‐onset obesity exhibited a mixed profile of metabolic health at baseline, including a higher degree of central adiposity and lower HbA1c and SBP. Improvements in BW and cardiometabolic markers with tirzepatide were similar between subgroups. Trial Registration ClinicalTrials.gov identifiers: NCT04184622, NCT04657016, NCT04660643 image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Endocrinology, Department of Pediatrics, Georgetown University, Washington, DC, USA.
- Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
- Department of Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
- Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
- Vanderbilt Weight Loss Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
ORCID-Profile: Evgenia Gourgari, Gitanjali Srivastava, Aaron S Kelly, Dachuang Cao, Chrisanthi A Karanikas, Clare J Lee
Förderung
- Eli Lilly and Company
Zitieren
APA
Gourgari, E., Srivastava, G., Kelly, A. S., Mojdami, D., Cao, D., Murphy, M. A., Karanikas, C. A., & Lee, C. J. (2025). Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials. Obesity. https://doi.org/10.1002/oby.24348
Vancouver
Gourgari E, Srivastava G, Kelly AS, Mojdami D, Cao D, Murphy MA, et al. Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials. Obesity. 2025. doi:10.1002/oby.24348
BibTeX
@article{Gourgari2025,
author = {Gourgari, Evgenia and Srivastava, Gitanjali and Kelly, Aaron S and Mojdami, Donna and Cao, Dachuang and Murphy, Madhumita A and Karanikas, Chrisanthi A and Lee, Clare J},
title = {Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials},
journal = {Obesity},
year = {2025},
doi = {10.1002/oby.24348}
}
EUVIMED